PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone610-981-6500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$670,000.00
Profitability
Miscellaneous
Employees22
Next Earnings Date3/24/2020 (Estimated)
OptionableNot Optionable
PhaseBio Pharmaceuticals (NASDAQ:PHAS) Frequently Asked Questions
What is PhaseBio Pharmaceuticals' stock symbol?
PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."
How were PhaseBio Pharmaceuticals' earnings last quarter?
PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) issued its quarterly earnings data on Thursday, November, 14th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.04. The business earned $0.24 million during the quarter, compared to analyst estimates of $0.35 million. PhaseBio Pharmaceuticals had a negative net margin of 1,768.29% and a negative return on equity of 53.00%. View PhaseBio Pharmaceuticals' Earnings History.
When is PhaseBio Pharmaceuticals' next earnings date?
What price target have analysts set for PHAS?
5 equities research analysts have issued twelve-month target prices for PhaseBio Pharmaceuticals' stock. Their forecasts range from $17.00 to $27.00. On average, they anticipate PhaseBio Pharmaceuticals' share price to reach $20.67 in the next year. This suggests a possible upside of 316.7% from the stock's current price. View Analyst Price Targets for PhaseBio Pharmaceuticals.
What is the consensus analysts' recommendation for PhaseBio Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PhaseBio Pharmaceuticals.
Has PhaseBio Pharmaceuticals been receiving favorable news coverage?
Media stories about PHAS stock have been trending somewhat positive on Wednesday, according to InfoTrie. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. PhaseBio Pharmaceuticals earned a coverage optimism score of 0.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for PhaseBio Pharmaceuticals.
Are investors shorting PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 2,600,000 shares, an increase of 13.5% from the January 15th total of 2,290,000 shares. Based on an average daily volume of 520,600 shares, the days-to-cover ratio is presently 5.0 days. Approximately 18.7% of the company's shares are short sold. View PhaseBio Pharmaceuticals' Current Options Chain.
Who are some of PhaseBio Pharmaceuticals' key competitors?
Some companies that are related to PhaseBio Pharmaceuticals include Assembly Biosciences (ASMB), Ardelyx (ARDX), Molecular Templates (MTEM), Kura Oncology (KURA), Crinetics Pharmaceuticals (CRNX), Neoleukin Therapeutics (NLTX), Axovant Sciences (AXON), Puma Biotechnology (PBYI), Milestone Pharmaceuticals (MIST), Arcus Biosciences (RCUS), MacroGenics (MGNX), Satsuma Pharmaceuticals (STSA), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX) and BioDelivery Sciences International (BDSI).
What other stocks do shareholders of PhaseBio Pharmaceuticals own?
Who are PhaseBio Pharmaceuticals' key executives?
PhaseBio Pharmaceuticals' management team includes the folowing people:
- Mr. Jonathan P. Mow, Pres, CEO & Director (Age 54)
- Mr. John P. Sharp, Chief Financial Officer (Age 54)
- Dr. John S. Lee, Chief Medical Officer (Age 51)
- Mr. Clay Bernardin Thorp, Chairman (Age 51)
- Mr. Michael B. York, VP of Corp. Devel. & Commercial Strategy (Age 54)
When did PhaseBio Pharmaceuticals IPO?
(PHAS) raised $66 million in an initial public offering on Thursday, October 18th 2018. The company issued 5,000,000 shares at a price of $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.
Who are PhaseBio Pharmaceuticals' major shareholders?
PhaseBio Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Farallon Capital Management LLC (3.48%), State Street Corp (0.80%), Sectoral Asset Management Inc (0.62%), Stifel Financial Corp (0.57%), Goldman Sachs Group Inc. (0.40%) and Parkman Healthcare Partners LLC (0.32%). Company insiders that own PhaseBio Pharmaceuticals stock include Clay Thorp, John P Sharp, Jonathan P Mow, Linda Tufts, Michael York, Nancy J Hutson and Venture Advisors Iii Hatteras. View Institutional Ownership Trends for PhaseBio Pharmaceuticals.
Which major investors are selling PhaseBio Pharmaceuticals stock?
Which major investors are buying PhaseBio Pharmaceuticals stock?
PHAS stock was purchased by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Parkman Healthcare Partners LLC, Virtu Financial LLC, Quantitative Systematic Strategies LLC, FNY Investment Advisers LLC, Acadian Asset Management LLC, State Street Corp and Goldman Sachs Group Inc.. Company insiders that have bought PhaseBio Pharmaceuticals stock in the last two years include Clay Thorp, John P Sharp, Jonathan P Mow, Linda Tufts, Michael York, Nancy J Hutson and Venture Advisors Iii Hatteras. View Insider Buying and Selling for PhaseBio Pharmaceuticals.
How do I buy shares of PhaseBio Pharmaceuticals?
Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is PhaseBio Pharmaceuticals' stock price today?
One share of PHAS stock can currently be purchased for approximately $4.96.
How big of a company is PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals has a market capitalization of $142.68 million and generates $670,000.00 in revenue each year. The company earns $-23,850,000.00 in net income (profit) each year or ($4.49) on an earnings per share basis. PhaseBio Pharmaceuticals employs 22 workers across the globe.View Additional Information About PhaseBio Pharmaceuticals.
What is PhaseBio Pharmaceuticals' official website?
How can I contact PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The company can be reached via phone at 610-981-6500 or via email at [email protected]
MarketBeat Community Rating for PhaseBio Pharmaceuticals (NASDAQ PHAS)
MarketBeat's community ratings are surveys of what our community members think about PhaseBio Pharmaceuticals and other stocks. Vote "Outperform" if you believe PHAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PHAS will underperform the S&P 500 over the long term. You may vote once every thirty days.
